NewcelX enters into a binding term sheet to spin off the legacy Mazindol (CVR) portfolio, providing upfront cash, equity ownership and up to $55 million in potential milestone payments.
NewcelX enters into a binding term sheet to spin off the legacy Mazindol (CVR) portfolio, providing upfront cash, equity ownership and up to $55 million in potential milestone payments.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in